Cargando…

SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)

Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with a profound impact on the evolution of patients with cancer, due to the potential development of serious complications, mortality, delays, and decrease in treatment intensity. This article seeks to present an updated cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmona-Bayonas, A., Jimenez-Fonseca, P., de Castro, E. M., Mata, E., Biosca, M., Custodio, A., Espinosa, J., Vázquez, E. G., Henao, F., Ayala de la Peña, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339667/
https://www.ncbi.nlm.nih.gov/pubmed/30470991
http://dx.doi.org/10.1007/s12094-018-1983-4
_version_ 1783388666740080640
author Carmona-Bayonas, A.
Jimenez-Fonseca, P.
de Castro, E. M.
Mata, E.
Biosca, M.
Custodio, A.
Espinosa, J.
Vázquez, E. G.
Henao, F.
Ayala de la Peña, F.
author_facet Carmona-Bayonas, A.
Jimenez-Fonseca, P.
de Castro, E. M.
Mata, E.
Biosca, M.
Custodio, A.
Espinosa, J.
Vázquez, E. G.
Henao, F.
Ayala de la Peña, F.
author_sort Carmona-Bayonas, A.
collection PubMed
description Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with a profound impact on the evolution of patients with cancer, due to the potential development of serious complications, mortality, delays, and decrease in treatment intensity. This article seeks to present an updated clinical guideline, with recommendations regarding the diagnosis, prevention, and treatment of febrile neutropenia in adults with solid tumors. The aspects covered include how to properly approach the risk of microbial resistances, epidemiological aspects, considerations about the initial empirical approach adapted to the risk, special situations, and prevention of complications. A decision-making algorithm is included for use in the emergency department based on a new, validated tool, the Clinical Index of Stable Febrile Neutropenia, which can be used in patients with solid tumors who appear stable in the initial phase of neutropenic infections, and can help detect those at high risk for complications in whom early discharge must be avoided.
format Online
Article
Text
id pubmed-6339667
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-63396672019-02-01 SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018) Carmona-Bayonas, A. Jimenez-Fonseca, P. de Castro, E. M. Mata, E. Biosca, M. Custodio, A. Espinosa, J. Vázquez, E. G. Henao, F. Ayala de la Peña, F. Clin Transl Oncol Clinical Guides in Oncology Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with a profound impact on the evolution of patients with cancer, due to the potential development of serious complications, mortality, delays, and decrease in treatment intensity. This article seeks to present an updated clinical guideline, with recommendations regarding the diagnosis, prevention, and treatment of febrile neutropenia in adults with solid tumors. The aspects covered include how to properly approach the risk of microbial resistances, epidemiological aspects, considerations about the initial empirical approach adapted to the risk, special situations, and prevention of complications. A decision-making algorithm is included for use in the emergency department based on a new, validated tool, the Clinical Index of Stable Febrile Neutropenia, which can be used in patients with solid tumors who appear stable in the initial phase of neutropenic infections, and can help detect those at high risk for complications in whom early discharge must be avoided. Springer International Publishing 2018-11-23 2019 /pmc/articles/PMC6339667/ /pubmed/30470991 http://dx.doi.org/10.1007/s12094-018-1983-4 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Guides in Oncology
Carmona-Bayonas, A.
Jimenez-Fonseca, P.
de Castro, E. M.
Mata, E.
Biosca, M.
Custodio, A.
Espinosa, J.
Vázquez, E. G.
Henao, F.
Ayala de la Peña, F.
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
title SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
title_full SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
title_fullStr SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
title_full_unstemmed SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
title_short SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
title_sort seom clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
topic Clinical Guides in Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339667/
https://www.ncbi.nlm.nih.gov/pubmed/30470991
http://dx.doi.org/10.1007/s12094-018-1983-4
work_keys_str_mv AT carmonabayonasa seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT jimenezfonsecap seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT decastroem seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT matae seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT bioscam seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT custodioa seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT espinosaj seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT vazquezeg seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT henaof seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018
AT ayaladelapenaf seomclinicalpracticeguidelinemanagementandpreventionoffebrileneutropeniainadultswithsolidtumors2018